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Borrelia burgdorferi, the Lyme disease agent, binds glycosaminoglycans (GAGs) such as heparin, heparan
sulfate, and dermatan sulfate. Heparin or heparan sulfate fractions separated by size or charge were tested for
their ability to inhibit attachment of B. burgdorferi to Vero cells. GAG chains of increasing length and/or charge
showed increasing inhibitory potency, and detectable heparin inhibition of bacterial binding required a
minimum of 16 residues. The ability of a given heparin fraction to inhibit binding to Vero cells was strongly
predictive of its ability to inhibit hemagglutination, suggesting that hemagglutination reflects the capacity of
B. burgdorferi to bind to GAGs.
Borrelia burgdorferi sensu lato is the spirochetal agent of
Lyme borreliosis, a chronic, multisystemic illness (12, 24). The
bacterium is acquired from an infected Ixodes tick, and after
infecting the skin at the site of the bite, it can disseminate
throughout the mammalian host. The ability of the spirochete
to bind to extracellular matrix or to the surface of host cells is
likely to promote tissue colonization, and the spirochete has
been shown to recognize several classes of host molecules (3, 4,
7, 8), including the glycosaminoglycan (GAG) heparin (11, 16).
GAGs consist of long, linear, highly sulfated disaccharide
repeats and are usually found covalently linked to a protein
core as a component of proteoglycans (13, 23). Based on the
extent and location of sulfation and on the composition of the
disaccharide unit, GAGs can be separated into different
classes, such as heparin, heparan sulfate, keratan sulfate, chon-
droitin-4-sulfate, chondroitin-6-sulfate, or dermatan sulfate.
Even within a given class of GAG there is extensive heteroge-
neity due to epimerization of the sugar backbone, differences
in chain length, and variations in the location of N-acetyl,
N-sulfate, and O-sulfate groups. The complexity and hetero-
geneity of GAGs complicate the analysis of protein-GAG
chain interactions.
B. burgdorferi has been shown to bind to heparin, heparan
sulfate, and dermatan sulfate, as well as to decorin, a dermatan
sulfate/chondroitin sulfate proteoglycan (8, 11, 16). B. burgdor-
feri strains that bind heparin have also been shown to aggluti-
nate rabbit erythrocytes in a heparin-inhibitable manner, sug-
gesting that the two activities may be linked (16). It is not clear
whether the recognition of different proteoglycans reflects
multiple binding pathways or a single, somewhat promiscuous
pathway. All GAG chains share the feature of high negative
charge, and charge has been demonstrated to be critical for B.
burgdorferi binding (11, 16). Nevertheless, charge is not the
sole determinant of binding, because not all GAG chains are
recognized by the spirochete, and the spectrum of GAGs that
are efficiently bound varies among different B. burgdorferi
strains (18). Thus, GAG binding by this bacterium displays an
element of specificity.
Characterization of the structural requirements for heparin
recognition by B. burgdorferi would promote a better under-
standing of the nature of this binding specificity as well as the
mechanisms of cell attachment and tissue colonization by this
pathogen. In the present study, we have identified some of the
features of GAG chain structure that are critical for cell at-
tachment by B. burgdorferi. We have further shown that these
features are also critical for inhibition of hemagglutination,
suggesting that B. burgdorferi GAG binding and hemagglutina-
tion are closely linked.
GAG chain charge and chain length are critical for recog-
nition by B. burgdorferi. Mammalian cell attachment by strain
N40, clone D10/E9 (an infectious B. burgdorferi sensu stricto
isolate [3]), is inhibited by the presence of exogenous dextran
sulfate, heparin, heparan sulfate, and dermatan sulfate (16,
17). This inhibition is due to an interaction between spiro-
chetes and GAG, because treatment of bacteria with GAG
inhibited cell binding even after excess GAG was removed by
washing (data not shown). In contrast, treatment of cell mono-
layers with GAG followed by washing resulted in no inhibition
of bacterial binding. Dextran and desulfated heparin failed to
inhibit attachment of B. burgdorferi, suggesting that a negative
charge is required for inhibitory activity (11, 16). To further
explore the relationship between charge and binding inhibi-
tion, we analyzed several GAG preparations that differed in
charge for the ability to inhibit B. burgdorferi N40 binding of
Vero (monkey kidney) cells, an interaction that was previously
shown to be mediated by proteoglycans (16). Attachment of
radiolabeled B. burgdorferi N40 to Vero cells was determined
in the presence of various concentrations of GAG, as described
elsewhere (16, 17). As previously shown, completely desul-
fated, N-acetylated heparin (Seikagaku, Inc., Tokyo, Japan)
had no detectable inhibitory activity, even when tested at 1
mg/ml (Table 1). N-desulfated, N-acetylated heparin, which
retains O sulfation, demonstrated weak inhibitory activity.
Fractions of heparan sulfate of different charge density, ob-
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tained from the laboratory of the late Isidore Danishefsky
(with the approval of the interim chairman, Ira Schwartz),
were also tested for inhibitory activity. Crude heparan sulfate,
derived from porcine intestinal mucosa (Cohelfred Laborato-
ries, Chicago, Ill.), was digested with chondroitinase ABC
(Seikagaku Inc.) and pronase B (Sigma Chemical Co., St.
Louis, Mo.), and the dialyzed product was purified on a DE-52
cellulose column (3.5 by 39 cm) and eluted with a linear gra-
dient of LiCl (0.4 to 1.5 M) in ammonium acetate buffer, pH
4.0. Fractions were ethanol precipitated and analyzed on a
Beckman amino acid analyzer, which revealed that they were
free of galactosamine and protein (data not shown). The mo-
lecular weight was estimated by migration on a 20% polyacryl-
amide gel, as described elsewhere (15, 22). The more highly
negatively charged fraction of heparan sulfate (HS-D) was a
better inhibitor of attachment than was the less highly nega-
tively charged fraction (HS-A) (Table 1).
Heparin (porcine; Sigma Chemical Co.) was also fraction-
ated by ion-exchange chromatography, using a QAE Sephadex
A-25 column as described elsewhere (21), and tested for the
ability to inhibit bacterial binding. A direct correlation was
observed between total charge and inhibitory potency (Table 1,
IE series fractions). For example, the 50% inhibitory concen-
tration (IC50) of fraction IE-4, which was eluted from the
ion-exchange column in 1.73 M salt, was 20-fold lower than the
IC50 of fraction IE-1, which was eluted in 1.50 M salt.
These heparin fractions differ not only in total charge but
also in median molecular weight, as estimated by Bio-Gel
P-100 gel filtration (21). Therefore, heparin fractionated by gel
filtration (from the laboratory of the late Isidore Danishefsky)
was also tested for inhibition of bacterial attachment (Table 1,
CF series fractions). Heparin (beef lung; Upjohn) was sepa-
rated on a 90- by 5-cm Bio-Gel P-100 column and eluted in
0.05 M Tris–0.5 M LiCl, pH 7.4, as described elsewhere (20).
The median molecular weight of each fraction was estimated
on the basis of sedimentation equilibrium (20) and confirmed
by high-performance liquid chromatography (data not shown).
As in the case of the heparin series that was fractionated by
charge, a direct correlation between GAG length and potency
was observed, indicating that both chain length and charge are
important factors governing GAG recognition by B. burgdor-
feri.
In Europe, two other B. burgdorferi sensu lato species, B.
garinii and B. afzelii, are also common agents of Lyme disease.
To test whether chain length is an important feature of GAG
recognition by other Lyme disease spirochetes, low- or high-
molecular-weight heparin fractions were assayed for their abil-
ity to inhibit Vero cell binding by B. burgdorferi sensu stricto
strain CA20-2A, B. garinii PBi, and B. afzelii VS461 (described
in reference 5). For each strain, the 21-kDa fraction of heparin
inhibited better than the 7-kDa fraction (Table 2).
A minimum chain length of 16 residues is required for
heparin to inhibit cell binding by B. burgdorferi. The correla-
tion between sugar chain length and inhibition prompted us to
test for a minimum size requirement for GAG recognition by
B. burgdorferi. Heparin fragments containing 10, 12, 16, 20, or
22 monosaccharide units (gifts of Ulf Lindahl [Department of
Medical and Physiological Chemistry, University of Uppsala,
Uppsala, Sweden] and Jean Choay [Institut Choay, Paris,
France] to the late Isidore Danishefsky [15, 19]) were tested
for the ability to inhibit bacterial attachment to Vero cells. The
22-mer almost completely blocked attachment, while the 10-
TABLE 1. Inhibition of cell attachment and hemagglutination by GAGs
GAGa Fraction Eluting concn ofLiCl (M)b
Estimated size
(kDa)
IC50 (mg/ml) for
cell attachmentc
MIC (mg/ml) for
hemagglutinationd
Heparin NAe NA NDf 6.3 0.16
Keratan sulfate NA NA ND .500 .500
Dermatan sulfate NA NA ND 32 100
Chondroitin-6-sulfate NA NA ND .500 .100
Chondroitin-4-sulfate NA NA ND .500 .100
Heparan sulfateg HS-D 0.75 6 170 .100
HS-A 0.55 17 .500 .100
Heparin
N-desulfated, N-acetylated NA NA ND 1,000 100
Completely desulfated,
N-acetylated
NA NA ND .1,000 .100
Fractionated by ion exchange IE-4 1.73 21.4 1.5 0.16
IE-3 1.64 19.7 3.5 20
IE-2 1.57 18.0 10.1 .100
IE-1 1.50 15.3 30.0 .100
Fractionated by gel filtration CF1 NA 21.0 3.9 0.032
CF2 NA 16.0 10.2 0.80
CF3 NA 12.0 11.2 4
CF4 NA 9.6 12.0 100
CF5 NA 7.0 51.0 100
a Unmodified and unfractionated GAGs were purchased from Sigma Chemical Co. Fractionated and modified GAGs were prepared as described in the text.
b GAG preparations separated by ion-exchange chromatography were eluted by the designated concentration of LiCl (21).
c The IC50 indicates the estimated concentration of GAG at which bacterial binding is 50% of the level of binding in the absence of inhibitor.
d The minimum concentration at which inhibition of hemagglutination could be detected for a given GAG preparation varied as much as fivefold from experiment
to experiment. We postulate that this variation was due to small differences in temperature, the age of the erythrocyte preparation, or other, unknown factors.
Nevertheless, the relative potency of each GAG fraction remained constant relative to that of dextran sulfate (500 kDa; Sigma Chemical Co.), which was included in
all experiments to provide standardization. Shown are the results of two experiments; all of the above GAG preparations except the IE heparin series were tested
simultaneously, and in that experiment, the MIC for dextran sulfate was 6.4 ng/ml. The IE series was tested on a separate occasion, and on that occasion, the MIC for
dextran sulfate was 32 ng/ml (data not shown).
e NA, not applicable.
f ND, not determined.
g Fractionated by ion exchange.
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and 12-mers had no effect (Fig. 1). The 16-mer (P , 0.05
versus no-inhibitor control) and 20-mer (P , 0.005) inhibited
at intermediate levels.
Inhibition of cell binding closely correlates with inhibition
of hemagglutination. It has been postulated that the GAG-
binding activity of B. burgdorferi is reflected by the agglutina-
tion of rabbit erythrocytes, because hemagglutination is inhib-
ited by heparin and those strains that exhibit low-level
hemagglutination activity also exhibit low-level GAG-binding
activity (16). A further prediction of this hypothesis is that the
ability of a given GAG preparation to inhibit cell attachment
should correlate with its ability to inhibit hemagglutination.
Used in these assays was a detergent extract of B. burgdorferi
N40, prepared in bulk and frozen in aliquots at 270°C, that
was found to give a more predictable hemagglutination titer
than intact spirochetes (the aggregation of which introduced
variability in the hemagglutination titer [data not shown]). To
generate this extract, a suspension containing 1011 B. burgdor-
feri N40 cells per ml was lysed by sonication, and the insoluble
fraction was extracted in a solution containing 2% deoxy-
cholate, 20 mM HEPES, 4 mM EDTA, and 0.01 trypsin-inhib-
itory units of aprotinin (Sigma Chemical Co.) per ml for 40 min
at 4°C. The hemagglutination activity of the detergent-soluble
fraction and the effect of each of the GAG preparations on this
activity were determined as described previously (16). When
we tested different classes of GAGs for the ability to inhibit
hemagglutination, keratan sulfate, chondroitin-4-sulfate, and
chondroitin-6-sulfate had no effect whereas heparin and der-
matan sulfate were inhibitory, the former at a much lower
concentration than the latter (Table 1). Completely desulfated,
N-acetylated heparin was devoid of hemagglutination blocking
activity, and N-desulfated, N-acetylated heparin retained weak
inhibitory activity. Fractions containing longer, more highly
charged heparin chains were better inhibitors than fractions
containing shorter, less highly charged fractions (IE and CF
series fractions, Table 1). All of these results paralleled inhi-
bition of Vero cell binding by the same GAG preparations, and
within the CF heparin fractionation series, the minimum con-
centration for inhibition of hemagglutination correlated with
the IC50 for cell attachment (Fig. 2).
Discussion. We undertook this study to better define the
requirements for GAG chain recognition by B. burgdorferi, and
we found that both the charge and the chain length of GAGs
are critical factors for bacterial binding. The length and/or
charge of the GAG chain correlated with inhibition of cell
binding by B. burgdorferi, and heparin chains with less than 16
residues lacked detectable inhibitory activity. Given the inti-
mate relationship between the size and total charge of GAGs,
it is difficult to assess the relative importance of these two
features for bacterial recognition.
The size of the heparin chain has been shown to be impor-
tant in heparin recognition by other pathogenic microorgan-
isms, such as Chlamydia trachomatis and Plasmodium falcipa-
rum (1, 2), and by many heparin-binding proteins as well (14).
The correlation between GAG length and inhibitory activity
for B. burgdorferi binding could indicate that the bacterial re-
ceptor for GAGs recognizes longer GAGs better. Alterna-
tively, the effective inhibition of bacterial binding to mamma-
TABLE 2. Size-dependent heparin inhibition of Vero cell binding
by diverse Lyme disease spirochetes
Heparin fraction
IC50 (mg/ml)a for:
B. burgdorferi B. garinii
PBi
B. afzelii
VS461N40 CA20-2A
Unfractionated 8.0 1.9 ,0.5 ,0.5
CF1 (21 kDa) 3.9 1.0 ,0.5 ,0.5
CF5 (7 kDa) 51.0 12.0 3.2 2.9
a The IC50 indicates the estimated concentration of GAG at which bacterial
binding is 50% of the level of binding in the absence of heparin. Size-fractionated
heparin preparations were prepared as described in the text. The specific lot of
unfractionated heparin from which CF1 and CF5 were derived was unavailable
for testing; thus, a different preparation of heparin was included for comparison.
FIG. 1. Identification of the minimum heparin fragment required for inhibi-
tion of attachment of B. burgdorferi to mammalian cells. Radiolabeled B. burg-
dorferi N40 was preincubated with 500 mg of heparin fragment per ml prior to
infection of Vero cells, and bound bacteria were quantitated. Each bar repre-
sents the average 6 the standard deviation of four determinations. Statistically
significant differences were determined by using Microsoft Excel to calculate
two-tailed t values between the no-inhibitor control (No Inhib.) and heparin
fractions; the asterisks indicate P values of ,0.05.
FIG. 2. The relative ability of heparin fractions to inhibit cell binding by B.
burgdorferi correlates with the ability to inhibit hemagglutination. The IC50 for
Vero cell binding and the minimum inhibitory concentration (MIC) for hemag-
glutination of each of the CF heparin fractions were determined as described in
Table 1. The nonparametric (Spearman) correlation coefficient r and the two-
tailed P value were calculated by using InStat version 2.01.
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lian cells may involve steric hindrance or electrostatic repulsion
between the bacterium and the host cell, features that are
likely to be provided better by longer heparin fragments. This
issue could be addressed by direct measurement of heparin-
spirochete interaction, but this would require either labeling of
each GAG preparation or the use of significantly larger quan-
tities of GAG (11, 16).
The results presented here suggest that the B. burgdorferi
heparin-binding component(s) is also responsible for this bac-
terium’s hemagglutinating activity. Those GAG preparations
that were potent inhibitors of cell binding were also potent
inhibitors of hemagglutination, and those preparations that did
not inhibit binding did not inhibit hemagglutination. A few
GAG preparations, such as heparan sulfate HS-A and heparin
fractions IE-1 and IE-2, inhibited cell binding but did not
inhibit hemagglutination, suggesting that inhibition of cell at-
tachment is a more sensitive method for detecting the GAG-
binding activity of B. burgdorferi.
B. burgdorferi has been demonstrated to bind to both hepa-
rin, heparan sulfate, and dermatan sulfate GAGs (11, 16, 17)
as well as to specific proteoglycans, such as decorin (8). It is not
known whether binding to multiple GAGs or proteoglycans
reflects a single or multiple mechanisms of cell attachment.
Two decorin-binding proteins have been identified (6, 9, 10),
but binding of B. burgdorferi to decorin was not inhibited by
heparin, suggesting that binding of heparin and binding of
decorin by this bacterium are distinct activities (8). The evi-
dence presented here suggesting that GAG binding by B. burg-
dorferi is strongly linked to hemagglutination provides a strat-
egy for evaluating candidate GAG-binding proteins and for the
purification and identification of the B. burgdorferi GAG-bind-
ing hemagglutinin(s).
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